Skip to Content


From the President

Promise -

More people die from lung cancer than from breast, prostate and colon cancers combined.

M. D. Anderson’s Lung Cancer Research Program is striving to change those statistics. We’re working hard to speed innovative therapies to the clinic through an array of clinical trials funded by the U.S. Department of Defense and philanthropy.

One of them, featured in this issue, is aptly named BATTLE (Biomarker- Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) as investigators continue their fight to beat this deadly disease. BATTLE is open to patients with late-stage non-small cell lung cancer. Its goal is to establish molecular-based, personalized targeted therapy by first examining the biomarker profiles of individual tumors, then assigning therapies that offer the best benefits based on those characteristics.

I’d also like to direct you to pages 4 and 5 and the 10 steps I proposed for the nation’s battle against cancer in a newspaper op-ed and at the National Press Club.

Your generosity, dedication and support are more important than ever before. Together, we can make a difference for cancer patients everywhere.

John Mendelsohn, M.D.

Spring 2009 Contents

© 2015 The University of Texas MD Anderson Cancer Center